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Objective
1. To derive and validate an accurate clinical prediction model
(“home score”) to estimate a patient’s risk of group A streptococcal
(GAS) pharyngitis before a health care visit based only on history
and real-time local biosurveillance, and to compare its accuracy to
traditional clinical prediction models composed of history and phys-
ical exam features. 2. To examine the impact of a home score on pa-
tient and public health outcomes.
Introduction
GAS pharyngitis affects hundreds of millions of individuals glob-
ally each year, and over 12 million seek care in the United States an-
nually for sore throat. Clinicians cannot differentiate GAS from other
causes of acute pharyngitis based on the oropharynx exam, so con-
sensus guidelines recommend use of clinical scores to classify GAS
risk and guide management of adults with acute pharyngitis. When
the clinical score is low, consensus guidelines agree patients should
neither be tested nor treated for GAS. A prediction model that could
identify very-low risk patients prior to an ambulatory visit could re-
duce low-yield, unnecessary visits for a most common outpatient con-
dition. We recently showed that real-time biosurveillance can further
identify patients at low-risk of GAS. With increasing emphasis on
patient-centric health care and the well-documented barriers imped-
ing clinicians’ incorporation of prediction models into medical prac-
tice, this presents an opportunity to create a patient-centric model for
GAS pharyngitis based on history and recent local epidemiology. We
refer to this model as the “home score,” because it is designed for use
prior to a physical exam.
Methods
Analysis of data collected from 110,208 patients 3 years and older
who presented with pharyngitis to a national retail health chain, from
2006-08. Practitioners collected standardized historical and physical
exam information based on algorithm-driven care, and all patients
with pharyngitis were tested for GAS. We used a previously validated
biosurveillance variable reflecting disease incidence called recent
local proportion positive (RLPP), which represents the proportion of
patients who tested GAS positive in a local market in the previous
14 days. To derive the “home score,” candidate variables were re-
stricted to demographic factors, historical items and the RLPP, while
physical exam variables (such as exudate), were excluded. Multi-
variate analytic techniques were used to identify predictors of GAS.
For each home score (0-100), we calculated the percent of patients
who tested positive, and we examined the relationship between the
home score and GAS positivity. Standard metrics (sensitivity, speci-
ficity, positive and negative predictive value, and AUC) were used to
compare the performance of the home score to standard scores. We
computed the number of patients aged >= 15 years who, according to
the home score, were at low risk for GAS, and therefore might avoid
or delay a trip to a medical provider. Outcomes included the num-
bers of reduced visits and the number of additional missed GAS cases
compared to the standard Centor score approach (Do not test/Do not
treat if Centor score is 0-1). To facilitate comparison across different
risk thresholds, we calculated outcomes for hypothetical cohorts of
1000 patients, and extrapolated these findings to provide the impact
on 12 million annual national pharyngitis visits.
Results
The 3 best predictors were fever (OR 2.43, 95%CI 2.33-2.54), ab-
sence of cough (1.71,1.63-1.80) and RLPP (1.04,1.04-1.04 per unit
change in RLPP). Using a home score cutoff of 0.10 to identify adults
at low risk would save 230,000 ambulatory visits annually while
missing only 8500 additional GAS cases. At a 0.20 cutoff, 2.9 million
visits would be saved, and 320,000 more cases missed each year.
There was a strong correlation between the percent testing positive
and the home score (r-square=0.98). As the home score increases,
there is a linear increase in the risk of GAS (slope=1.02). The home
score AUC was 0.66, approaching the Centor score (0.69) even with-
out any physical exam information.
Conclusions
A biosurveillance-driven home score to guide treatment of strep
pharyngitis could save millions of visits annually by identifying pa-
tients in the pre-visit setting who would be unlikely to be tested or
treated.
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